TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: A Study of the Efficacy and Safety of Topiramate in Epilepsy Patients With Primary Generalized Tonic-clonic Seizures

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Body weight \>25 kilograms (55 pounds)~* diagnosis of primary generalized epilepsy~* must have primary generalized tonic-clonic (PGTC) seizures treated with 1 or 2 antiepileptic drugs~* must have three PGTC seizures during baseline period, with at least 1 during each 28-day period of baseline~* females must not have had their first menstrual period or be postmenopausal, or are physically incapable of child bearing, or if of child bearing potential, sexually abstinent, or using adequate birth control measures, and have a negative pregnancy test before study entry.~Exclusion Criteria:~* Patients who do not have epilepsy, such as those with a treatable cause of seizure (for example, active infection or cancer)~* patients with progressive disorders (for example, active infection, cancer or metabolic disturbance)~* patients diagnosed with Lennox-Gastaut syndrome~* history of seizures occurring in only cluster patterns (numerous seizures occurring over a short period of time \[\<30 minutes\])~* documented history (previous 3 months) of generalized tonic-clonic status epilepticus (status epilepticus is a prolonged seizure or seizures repeated frequently over 20 to 30 minutes so that recovery between episodes does not occur) while receiving appropriate antiepileptic medication.

- Gender: ALL
- Minimum Age: 4 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Hylenex-Assisted Resuscitation in Kenya (HARK) Trial for the Management of Dehydration

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* All patients presenting to a participating facility with moderate-to-severe dehydration will be considered for participation. Other inclusion criteria will include:~* Patients over the age of 1 month~* Patients presenting with moderate-to-severe dehydration who failed to improve or are not candidates for oral rehydration therapy and IV access is not successful twice~* Parents or legal guardian(s) available to provide written informed consent~Exclusion Criteria:~* There will be no limitation based on race, tribe, language, or sexual orientation in the study for any patients who meet treatment criteria. There are no exclusions based on language. Exclusion criteria will include:~* Any condition precluding SC infusion or infusion-site evaluation in all possible anatomic locations, including the upper back, anterior thighs, abdomen, and other potential areas for hSC therapy~* Any reason (before study enrollment) for a hospital admission or extended stay for other than dehydration-related illness~* Known hypersensitivity to hyaluronidase or any ingredient in the study formulation of recombinant human hyaluronidase~* Any patient not eligible for IV or SC fluids as determined by the local clinician~* Any medical condition likely to interfere with the patient's ability to fully complete all protocol-specified interventions, the ability to undergo all protocol-specified assessments, or likely to prolong the patient's need for medical attention beyond that required for addressing the dehydration-related illness

- Gender: ALL
- Minimum Age: 1 Month
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- hyaluronic acid (Type: EXPERIMENTAL): Rehydration using hyaluronidase-assisted subcutaneous infusion

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Phase 2 Study of XAF5 (XOPH5) Ointment for Reduction of Excess Eyelid Fat (Steatoblepharon)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria (abbreviated):~* Moderate to severe lower eyelid steatoblepharon (LESS score of 2-4 bilaterally)~* Men and women 40-70 years old~* Healthy facial skin~* Must understand and provide informed consent~Exclusion Criteria (abbreviated):~* Best corrected visual acuity worse than 20/40 in either eye~* Regular use of ophthalmic medication in either eye~* Planned use of contact lenses during the study~* Any history of lower eyelid surgery

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- XOPH5 Ointment (Type: EXPERIMENTAL): XOPH5 Ointment is the investigational drug to be studied.
- Placebo Ointment (Type: PLACEBO_COMPARATOR): Placebo is an ointment that matches XOPH5 Ointment but lacks the active ingredient.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of Faricimab (RO6867461) in Participants With Center-Involving Diabetic Macular Edema

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Macular edema associated with diabetic retinopathy~* Decreased visual acuity attributable primarily to DME~* Diagnosis of diabetes mellitus~Exclusion Criteria:~* High risk proliferative diabetic retinopathy~* Cataract surgery within 3 months of Baseline, or any other previous intraocular surgery~* Uncontrolled glaucoma~* Current or history of ocular disease in the study eye other than DME~* Major illness or major surgical procedure within 1 month prior to Day 1~* Uncontrolled blood pressure~* Glycosylated hemoglobin (HbA1c) greater than (\>) 12 percent (%) at screening~* Untreated diabetes mellitus or initiation of oral anti-diabetic medication or insulin within 4 months prior to Day 1

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm A: 0.3 mg Ranibizumab (Type: ACTIVE_COMPARATOR): Participants will receive 0.3 milligrams (mg) ranibizumab every fourth week up to Week 20, for a total of 6 administrations, followed by an observational period up to Week 36. If a participant meets pre-specified criteria the participant will receive a single dose of 0.3 mg ranibizumab and exit the study.
- Arm B: 1.5 mg Faricimab (Type: EXPERIMENTAL): Participants will receive 1.5 mg faricimab every fourth week up to Week 20, for a total of 6 administrations, followed by an observational period up to Week 36. If a participant meets pre-specified criteria the participant will receive a single dose of 0.3 mg ranibizumab and exit the study.
- Arm C: 6 mg Faricimab (Type: EXPERIMENTAL): Participants will receive 6 mg faricimab every fourth week up to Week 20, for a total of 6 administrations, followed by an observational period up to Week 36. If a participant meets pre-specified criteria the participant will receive a single dose of 0.3 mg ranibizumab and exit the study.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of House Dust Mite Allergoid in the Treatment of Bronchial Asthma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Bronchial asthma~* Requirements for inhaled corticosteroid~* Positive skin prick test to house dust mite~* Positive radioallergosorbent test (RAST) to house dust mite~* Positive provocation test result to house dust mite~Exclusion Criteria:~* Serious chronic diseases~* Other perennial allergies

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: 40 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Placebo was given the same way as a subcutaneous (just under the skin) injection. Children received lifestyle counselling.
- Acaroid (Type: EXPERIMENTAL): The drug tested in this study (aluminium hydroxide-adsorbed house dust mite (D. pteronyssinus) allergoid preparation) was given as a subcutaneous injections of increasing doses.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Topical Imiquimod in Conjunction With Nd:YAG Laser for Tattoo Removal

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* 2 tattoos no larger than 25cm2, professionally made, with approximately the same age, containing blue/black ink.~Exclusion Criteria:~* Hypersensitivity to imiquimod~* Current sun tan~* Use of vitamin E, non-steroid anti-inflammatory drugs, coumadin or aspirin for the past 10 days~* Amateur tattoos~* Pregnancy~* Breast-feeding status~* Immunosuppression~* Auto-immune diseases.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- 1 (Type: ACTIVE_COMPARATOR): The tattoo will be treated with laser and imiquimod 5% cream
- 2 (Type: PLACEBO_COMPARATOR): The tattoo will be treated with laser and placebo topical cream

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effects of Added D-fagomine on Glycaemic Responses to Sucrose

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female (not less than 40% Male)~* Aged 18 - 55 years~* Have a body mass index between 18.5 to 29.99 kg/m2~* Healthy, non-diabetic, no gastric bypass surgery~* Have a fasting plasma glucose (finger-stick) \<100 mg/dl (\<5.5 mmol/L)~* Willing and able to provide written informed consent~Exclusion Criteria:~* Smokers~* Allergic to dairy or soy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: t

Study Arms:
- D-fagomine (Type: EXPERIMENTAL): Measure the changes produced on the postprandial Glycaemic response to 50 g of sucrose containing 40 mg D-fagomine, in 200 ml water
- Control (Type: PLACEBO_COMPARATOR): Sucrose 50 g without d-fagomine, in 200 ml water

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate SAGE-547 in Participants With Severe Postpartum Depression

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Key Inclusion Criteria:~* Participant either must have ceased lactating at Screening; or if still lactating at Screening, must have already fully and permanently weaned their infant(s) from breastmilk; or if still actively breastfeeding at Screening, must agree to cease giving breastmilk to their infant(s) prior to receiving study drug.~* Participant had a major depressive episode that began no earlier than the third trimester and no later than the first 4 weeks following delivery, as diagnosed by Structured Clinical Interview for DSM-IV Axis I Disorders (SCID-I).~* Participant was less than or equal to (\<=) six months postpartum.~* Participant must be amenable to intravenous therapy.~Key Exclusion Criteria:~* Active psychosis.~* Attempted suicide associated with index case of postpartum depression.~* Medical history of seizures.~* Medical history of bipolar disorder.~Note: suicidal ideation was not an exclusion. Other protocol-defined inclusion/exclusion criteria may apply.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Participants received infusion rates of placebo matched to SAGE-547.
- SAGE-547 (Type: EXPERIMENTAL): Participants received a 4-hour dose titration of 30 micrograms per kilogram per hour (micrograms/kg/hr) (0 to 4 hours), then 60 micrograms/kg/hr (4 to 24 hours), then 90 micrograms/kg/hr (24 to 52 hours), followed by a taper to 60 micrograms/kg/hr (52 to 56 hours), and 30 micrograms/kg/hr (56 to 60 hours).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The Anti-fungal Effect of Miconazol Versus Miconazol-Loaded Chitosan Nanoparticles

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. uncontrolled diabetes patients with oral candidiasis and their uncontrolled diabetes were confirmed by doing glycated hemoglobin test and their range is \>7.0%,~2. age ranged from 30-65 years~3. patients were willing to participate in this study~Exclusion Criteria:~1. immunocompromised and patients with systemic diseases that can cause muscle weakness as Parkinson's disease, or others that can limit their cognitive functioning such as dementia~2. pregnant~3. nursing women~4. smokers~5. alcoholic patients were also excluded from the study.~6. should not have a history of use of any drugs that can cause hyposalivation or broad spectrum antibiotics, within the last month.

- Gender: ALL
- Minimum Age: 30 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- interventional (Type: EXPERIMENTAL): chitosan loaded with miconazole nanoparticles gel
- control (Type: EXPERIMENTAL): miconazole gel

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of the Safety and Efficacy of Botox in Bruxism

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* 1. Patients between the ages of 18 and 80 years old with a diagnosis of bruxism, based on the standard criteria.~* 2. If the subject is a female of childbearing age, she must have had a hysterectomy, tubal ligation, or otherwise be incapable of pregnancy, or have practiced a method of contraception (hormonal contraceptives, spermicidal barrier, intrauterine device, partner sterility) at least one month prior to study entry. Any female of childbearing age will have a urine pregnancy test one week prior to the treatment (visit 2).~* 3. Ability of the patient or guardian to sign and understand informed consent.~* 4. Ability to follow and comply with study directions.~Exclusion Criteria:~* 1. Coexistence of active psychosis, other active psychiatric disease or cognitive impairment.~* 2. Coexistence of serious co-morbid conditions.~* 3. Exposure to any botulinum toxin preparation within the past 6 months.~* 4. Participation in another experimental therapeutic protocol within 30 days.~* 5. Any medical condition in which the administration of botulinum toxin is contraindicated, including myasthenia gravis, amyotrophic lateral sclerosis or other neuromuscular diseases.~* 6. History of dysphagia.~* 7. History of botulism.~* 8. A condition or situation in which the investigators view will confound the ability of the subject to participate in the study.~* 9. Patients or guardian who are unable to understand and sign informed consent.~* 10. Pregnancy~* 11. Patients who do not meet inclusion criteria.~* 12. Patients in whom it is felt that a major portion of overall sleep morbidity is not related to bruxism.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Placebo arm
- botulinum toxin type A (Type: ACTIVE_COMPARATOR): Active arm

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Niraparib as Maintenance Therapy in Patients With Platinum Sensitive Recurrent Ovarian Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: RETROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Female participants 18 years old or older.~* Participant must be able to understand the study procedures and agree to participate in the study by providing written informed consent.~* Participant must have received niraparib within the Spanish expanded access program (EAP).~* Patients must have received at least 1 week of treatment with niraparib.~* Histological diagnosis of high grade serous ovarian cancer, fallopian tube cancer, or primary peritoneal cancer.~* Participants must have completed at least 2 previous courses of platinum-containing therapy (e.g., carboplatin, oxaliplatin, or cisplatin).~* For the penultimate (next to last) platinum-based chemotherapy course prior to enrolment on the program the patient must have platinum sensitive disease after this treatment; defined as achieving a response (complete response (CR) or partial response (PR)) and disease progression occurring no sooner than 6 months, after completion of the last dose of platinum chemotherapy.~* For the last chemotherapy course prior to inclusion in the program the patient must have received a platinum-containing regimen for a minimum of 4 cycles.~* For the last chemotherapy course prior to inclusion in the program the Patient must have achieved a partial (PR) or complete (CR) tumor response.~* The last platinum regimen does not necessarily have to immediately follow the next to last (penultimate) platinum regimen. For example, if a patient received a non-platinum regimen between the penultimate platinum regimen and last platinum regimen, they could be eligible, so long as they meet all entry criteria.~* When entering the EAP, patients must have met the following:~  * Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1.~ * Adequate organ function - Absolute neutrophil count (ANC) ≥ (greater than or equal to) 1,500/μL.~ * Adequate organ function - Platelets ≥ (greater than or equal to) 100,000/μL.~ * Adequate organ function - Hemoglobin ≥ (greater than or equal to) 9 g/dL.~ * No transfusions of erythrocytes or platelets within 2 weeks prior to assessing adequate hematological blood counts as listed above.~Exclusion Criteria:~* Patients without medical record available (lost, empty or unretrievable clinical information).~* Patients who decline consent.~* Patients who are deceased with prior express order to preserve their data.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of Effect of Intravenous Morphine vs Intravenous Ibuprofen and Acetaminophen vs Intravenous Ibuprofen

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosing a closed fracture of any of the bones of the body by an emergency medicine specialist~* Informed consent of the patient or his family to participate in the study~* Age 18 to 55 years~* Pain score of higher than or equal to 6 on the VAS scale~* Informed consent of the patient or family during the study~* No history of liver or kidney failure~* No history of gastrointestinal bleeding~* No history of heart failure~* No history of allergy to study drugs~* Absence of addiction (the patient is asked)~* Not decreased level of consciousness~* Lack of evidence of increased intra-cerebral pressure~* Not having an open fracture~* Absence of breathing disorders and respiratory problems~* No history of asthma~* Lack of history of frequent use of painkillers~* Not receiving any form of pain killer in the last few hours~Exclusion Criteria:~* Occurrence of any type of drug reaction or unusual complication during the study period~* Simultaneous Head trauma~* Simultaneous damage of nerves and blood vessels~* Multiple fractures~* Fracture other than limb~* Evidence of increased intra-cerebral pressure~* Decreased level of consciousness~* Breathing disorders and respiratory problems

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: f

Study Arms:
- Ibuprofen (Type: ACTIVE_COMPARATOR): Ibuprofen 800 mg IV infusion over 20 min.
- Morphine (Type: ACTIVE_COMPARATOR): Morphine Sulfate 0.1 mg/kg IV
- Ibuprofen plus Acetaminophen (Type: ACTIVE_COMPARATOR): Ibuprofen 400 mg plus Acetaminophen 1000 mg IV infusion over 20 min.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete